Clinical trials: Prostatic Disease
Prostatic Neoplasm
CT/MRI Co-registration Prostate Cancer
The target volume in prostate cancer radiotherapy typically consists of the entire prostate gland which is localized by contours drawn on axial computed tomography (CT) radiation planning images.
- Trial name
- NCT00252460
- Testing
- Computed Tomography Scan and Magnetic Resonance Imaging
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- University Health Network, Toronto
Prostatic Neoplasms
PK, PD, Tolerability and Safety of MDPK67b in Healthy Volunteers
This is a Phase I, single centre, prospective, randomized, alternating panels, ascending doses with interspersed placebo, double-blind, crossover trial.
- Trial name
- NCT04839120
- Testing
- MDPK67b
- Where
- Switzerland
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Med Discovery SA
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Benign Prostatic Hyperplasia
Protocollo N 2014 - Benign Prostatic Hyperplasia
Prospective observational study on the quality of life of patients with BPH under medical therapy and/or undergoing surgery.
- Trial name
- NCT06182189
- Testing
- Observation of patients with a benign prostatic hyperplasia condition
- Where
- Italy
- Volunteers
- 8,000 people
- Sponsor
- IRCCS San Raffaele
Prostate Cancer, PSMA PET/CT
Brief Title: INTROSPECT: Intraoperative PSMA PET/CT Imaging During Radical Prostatectomy
During prostate cancer surgery, the surgeon aims to remove the tumor completely while preserving the surrounding tissue responsible for urinary continence and sexual potency.
- Conditions
- Prostate Cancer, PSMA PET/CT, Margin Assessment
- Trial name
- INTROSPECT (NCT07829068)
- Testing
- study-specific administration of 68Ga-PSMA-11 followed by ex vivo PET/CT imaging of the prostatectomy specimen
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University Hospital, Geneva
Prostate Cancer
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
This study will look at the effect of adding the drug Palbociclib to CAD (Combined Androgen Deprivation) therapy in patients with RB (Retinoblastoma Protein) positive hormone sensitive prostate cancer.
- Trial name
- NCT02059213
- Testing
- Ibrance, Bicalutamide, Zoladex
- Where
- 8 sites in United States
- Volunteers
- 72 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Castration-resistant Prostate Cancer
The COSMYC Trial (COmbined Suppression of MYC)
This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that…
- Trial name
- NCT06922318
- Testing
- ZEN-3694, Testosterone cypionate, Enzalutamide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body.
- Trial name
- NCT04663997
- Testing
- 177Lu-PSMA-617, Docetaxel
- Where
- 10 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Canadian Cancer Trials Group
Benign Prostatic Hyperplasia
Observational Study to Evaluate Effect of Thrupas® Capsule on Cardiovascular System
To evaluate effect on cardiovascular system(blood pressure) when Thrupas® capsule is administered every day for 12 weeks in patients with Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia
- Trial name
- CV (NCT02029560)
- Where
- 4 sites in South Korea
- Volunteers
- 400 people
- Sponsor
- JW Pharmaceutical
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Physical Activity, Metabolic Syndrome
Exercise Intervention Metabolic Syndrome Prostate Cancer Black Men
The main purpose of this study is to examine the feasibility of an exercise intervention on metabolic syndrome (MetS) components and biomarkers related to prostate cancer in Black men with MetS who are at increased risk of…
- Conditions
- Physical Activity, Metabolic Syndrome, Prostate Cancer
- Trial name
- STRONG (NCT02379559)
- Testing
- Exercise, Attention Control
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Georgetown University
Prostate Cancer
Casodex/Zoladex Biomarkers in Localised Prostate Cancer
To evaluate anti-androgen (bicalutamide) induced biological and molecular changes in prostate comparison to chemical castration induced (goserelin) ones
- Trial name
- NCT00293696
- Testing
- bicalutamide (Casodex), goserelin (Zoladex)
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- Tampere University
Prostate Cancer
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
The primary objective of this study is to compare the progression free survival (PFS) of patients with metastatic castration-resistant prostate cancer treated with enzalutamide in combination with LY2157299 (Arm 1) versus…
- Trial name
- NCT02452008
- Testing
- Enzalutamide, LY2157299
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer Metastatic
A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer
This study is a multicenter phase I/II study of the treatment of patients with metastatic prostate cancer. The objective of Phase I part is to study the safety and tolerability of LAE001 monotherapy in patients with metastatic…
- Trial name
- NCT03843918
- Testing
- LAE001
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Laekna Limited
Prostate Cancer, Osteoporosis
Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent
Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen
- Trial name
- NCT01025479
- Where
- 18 sites in South Korea
- Volunteers
- 829 people
- Sponsor
- AstraZeneca
Oligometastatic Disease, Prostate Cancer
Percutaneous High-dose Radiotherapy in Patients With Oligometastases of Prostate Carcinoma
The purpose of this study is to evaluate the outcomes of patients treated with an high dose radiation regimen using either stereotactic hypofractionated or normofractionated radiotherapy for oligometastatic prostate cancer and to…
- Trial name
- Oli-P (NCT02264379)
- Testing
- normal fractionated irradiation, hypo fractionated irradiation
- Where
- 2 sites in Germany
- Volunteers
- 73 people
- Sponsor
- Technische Universität Dresden
Prostate Adenocarcinoma
CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
The primary objective of this study is to document the effectiveness of Cyberknife stereotactic body radiotherapy (SBRT) in the treatment of intermediate and high-risk localized prostate cancer defined by biochemical Disease-Free…
- Trial name
- NCT01985828
- Testing
- CyberKnife, Androgen Deprivation Therapy (ADT), Intensity Modulated radiation therapy (IMRT)
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Wake Forest University Health Sciences
Localized Prostate Carcinoma
24 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer
Patients with prostate cancer who are candidates for stereotactic radiotherapy to the prostate and seminal vesicles will undergo staging exams, which will include prostate specific membrane antigen (PSMA) positron emission…
- Trial name
- PRO-FAST (NCT05936736)
- Testing
- prostate SBRT
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- IRCCS San Raffaele
Urinary Retention
First-in-man Safety and Efficacy Trial of a Novel Non-invasive Bladder Emptying Device: The NIBED Study
The non-invasive bladder emptying device (NIBED) is a handheld medical device that is applied to the penis during urinating to aid bladder emptying in urinary retention patients with increased residual urine volume.
- Trial name
- NIBED pilot (NCT04919798)
- Testing
- Non-invasive bladder emptying device
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Prostate Cancer
Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
This is a pilot multimodality treatment approach trial with androgen deprivation therapy in combination with docetaxel chemotherapy followed by radical prostatectomy in patients with newly diagnosed high-risk and oligometastatic…
- Trial name
- NCT03358563
- Testing
- Docetaxel, Degarelix, Bicalutamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Wisconsin, Madison
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.